Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xevinapant - Merck & Co

Next Previous
X
Search
Drug Profile

Xevinapant - Merck & Co

Alternative Names: AT 406; Debio-1143; SMAC mimetic - Debio-1143

Latest Information Update: 27 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascenta Therapeutics
  • Developer 3SBio; Ascenta Therapeutics; Debiopharm; EMD Serono; Merck & Co; The Leukemia & Lymphoma Society
  • Class Amides; Antineoplastics; Aza compounds; Benzene derivatives; Pyrroles; Radiation-sensitising agents; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Squamous cell cancer
  • Phase I Glioma
  • Discontinued Acute myeloid leukaemia; Adenocarcinoma; Leukaemia; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 19 Sep 2024 EMD Serono, in collaboration with Merck & Co terminates phase I trial in Squamous cell cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, First-line therapy) in USA, Belgium, South Korea, Spain, Taiwan (PO), as no major safety concerns were identified in study, but lack of evidence of efficacy of meaningful clinical benefit (NCT06056310)
  • 19 Aug 2024 Discontinued - Phase-I for Acute myeloid leukaemia (Combination therapy) in USA (PO)
  • 19 Aug 2024 Discontinued - Phase-I for Adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease) in France (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top